Condition: Renal Cell Carcinoma · Neoadjuvant · Sponsor: ZHOU FANGJIAN
The study included 298 RCC patients who were at high risk for recurrence after nephrectomy (T2G3-4 or T3-4 or N1). They were randomly divided to receive axitinib plus PD-1 + surgery or surgery alone at a ratio of 1:1, so as to determine the efficacy of the neoadjuvant combination of axitinib plus PD-1.
This description comes directly from the study's public registry record.
Zhiling Zhang, Professor · +86-020-87343860 · zhangzhl@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, China | Recruiting |
| Peking University First Hospital | Beijing, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, China | Recruiting |
| Anhui Provincial Hospital | Hefei, China | Recruiting |
| Fudan University Cancer Hospital | Shanghai, China | Recruiting |
| West China Hospital | Sichuan, China | Recruiting |
| Tianjin Medical University Cancer Institute and Hospital | Tianjin, China | Recruiting |
| The First Affiliated Hospital of Zhengzhou Hospital | Zhengzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05738694